Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.47 |
| ▸ | BACE1 | P56817 | 1/20 | 0.47 |
| ▸ | MDM4 | O15151 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | YAP1 | P46937 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | TLR2 | O60603 | 1/20 | 0.42 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31627392 | 0.94 | BACE1 (0.53) | IDO1MAPK1MDM2BACE1MDM4 | |
| SCHEMBL25356332 | 0.94 | BACE1 (0.53) | IDO1MAPK1MDM2BACE1MDM4 | |
| SCHEMBL5434114 | 0.94 | BACE1 (0.53) | IDO1MAPK1MDM2BACE1MDM4 | |
| SCHEMBL25355242 | 0.94 | BACE1 (0.53) | IDO1MAPK1MDM2BACE1MDM4 | |
| SCHEMBL25356064 | 0.85 | MDM4 (0.48) | IDO1MDM2BACE1MDM4TP53 | |
| SCHEMBL25356055 | 0.85 | MDM4 (0.48) | IDO1MDM2BACE1MDM4TP53 | |
| SCHEMBL25356058 | 0.85 | MDM4 (0.48) | IDO1MDM2BACE1MDM4TP53 | |
| SCHEMBL30639799 | 0.85 | BACE1 (0.52) | IDO1MDM2BACE1MDM4TP53 | |
| SCHEMBL30639789 | 0.85 | BACE1 (0.52) | IDO1MDM2BACE1MDM4TP53 | |
| SCHEMBL26105252 | 0.85 | BACE1 (0.52) | IDO1MDM2BACE1MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10913769-B2 | Synthetic peptide amides and dimers thereof | CARA THERAPEUTICS, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| US-20190177365-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERS THEREOF | CARA THERAPEUTICS, INC. (US) | 2019-06-13 | — | — | US | disclosed |
| US-10017536-B2 | Synthetic peptide amides and dimers thereof | CARA THERAPEUTICS, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20160376308-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERS THEREOF | CARA THERAPEUTICS, INC. (US) | 2016-12-29 | — | — | US | disclosed |
| US-9334305-B2 | Synthetic peptide amides and dimers thereof | CARA THERAPEUTICS, INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-20140357579-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERS THEREOF | VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA LTD (CH) | 2014-12-04 | — | — | US | disclosed |
| CN-101535336-B | Synthetic phthalamides and dimers thereof | CARA THERAPEUTICS INC | 2014-04-02 | — | — | CN | disclosed |
| US-8536131-B2 | Synthetic peptide amides and dimers thereof | CARA THERAPEUTICS, INC. (US) | 2013-09-17 | — | — | US | disclosed |
| US-8486894-B2 | Synthetic peptide amides and dimeric forms thereof | CARA THERAPEUTICS, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| EP-2079756-B1 | SYNTHETIC PEPTIDE AMIDES AND DIMERS THEREOF | CARA THERAPEUTICS INC (US) | 2012-10-17 | — | — | EP | disclosed |
| US-20110257105-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERS THEREOF | CARA THERAPEUTICS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110118186-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | CARA THERAPEUTICS, INC. (US) | 2011-05-19 | — | — | US | disclosed |
| US-7842662-B2 | of kappa opioid receptor and agonists thereof, exhibit low P450 CYP inhibition and low penetration into the brain; visceral pain, neuropathic pain, hyperalgesia, irritabile bowel syndrome, ocular and otic inflammation, pruritis, edema, hyponatremia, hypokalemia, ileus, tussis and glaucoma | CARA THERAPEUTICS, INC. (US) | 2010-11-30 | — | — | US | disclosed |
| US-7713937-B2 | Synthetic peptide amides and dimeric forms thereof | CARA THERAPEUTICS, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-20100075910-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | CARA THERAPEUTICS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20090264373-A1 | of kappa opioid receptor and agonists thereof, exhibit low P450 CYP inhibition and low penetration into the brain; visceral pain, neuropathic pain, hyperalgesia, irritabile bowel syndrome, ocular and otic inflammation, pruritis, edema, hyponatremia, hypokalemia, ileus, tussis and glaucoma | CARA THERAPEUTICS, INC. (US) | 2009-10-22 | — | — | US | disclosed |
| CN-101535336-A | Synthetic phthalamides and dimers thereof | SYNTHETIC PEPTIDE AMIDES AND D (US) | 2009-09-16 | — | — | CN | disclosed |
| EP-2079756-A2 | SYNTHETIC PEPTIDE AMIDES AND DIMERS THEREOF | Cara Therapeutics, Inc. (US) | 2009-07-22 | — | — | EP | disclosed |
| US-20090156508-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | CARA THERAPEUTICS, INC. (US) | 2009-06-18 | — | — | US | disclosed |
| WO-2008060552-A2 | SYNTHETIC PEPTIDE AMIDES AND DIMERS THEREOF | CARA THERAPEUTICS, INC. (US) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160376308-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERS THEREOF | OPRK1, OPRL1, OPRM1 | IDO1 614/4885MAPK1 1605/4885MDM2 3623/4885 |
| US-20100075910-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | OPRK1, OPRD1, OPRM1 | IDO1 303/4885MAPK1 1876/4885MDM2 4041/4885 |
| US-20090156508-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | OPRK1, OPRM1, OPRL1 | IDO1 347/4885MAPK1 1634/4885MDM2 4499/4885 |
| US-20110118186-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | OPRK1, OPRM1, OPRL1 | IDO1 347/4885MAPK1 1634/4885MDM2 4499/4885 |
| US-20090264373-A1 | of kappa opioid receptor and agonists thereof, exhibit low P450 CYP inhibition and low penetration into the brain; visceral pain, neuropathic pain, hyperalgesia, irritabile bowel syndrome, ocular and otic inflammation, pruritis, edema, hyponatremia, hypokalemia, ileus, tussis and glaucoma | OPRK1, OPRD1, OGFR | IDO1 117/4885MAPK1 767/4885MDM2 3924/4885 |
| US-10913769-B2 | Synthetic peptide amides and dimers thereof | OPRK1, OPRL1, OPRM1 | IDO1 614/4885MAPK1 1605/4885MDM2 3623/4885 |
| US-20140357579-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERS THEREOF | OPRK1, OPRL1, OPRM1 | IDO1 614/4885MAPK1 1605/4885MDM2 3623/4885 |
| US-20110257105-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERS THEREOF | OPRK1, OPRL1, OPRM1 | IDO1 614/4885MAPK1 1605/4885MDM2 3623/4885 |
| US-10017536-B2 | Synthetic peptide amides and dimers thereof | OPRK1, OPRL1, OPRM1 | IDO1 614/4885MAPK1 1605/4885MDM2 3623/4885 |
| US-20190177365-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERS THEREOF | OPRK1, OPRL1, OPRM1 | IDO1 614/4885MAPK1 1605/4885MDM2 3623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.